Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xencor Inc. (XNCR)
:XNCR
XNCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$15.31 - $27.24
Previous CloseN/A
Volume126.93K
Average Volume (3M)497.60K
Market Cap
$1.11B
Enterprise Value$828.17M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Mar 03, 2025EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.20
Shares Outstanding69,982,030
10 Day Avg. Volume458,696
30 Day Avg. Volume497,602
Standard Deviation0.12
R-Squared0.10
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)13.31
Price to Cash Flow (P/CF)-10.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.71
Enterprise Value/Ebitda-4.33
Forecast
1Y Price Target
$33.75Price Target Upside113.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Xencor News
PremiumCompany Announcements
Xencor Highlights Progress in Drug Development Pipeline
PremiumCompany Announcements
Xencor Reports Q3 2024 Earnings and Program Updates
PremiumPre-Earnings
Is XNCR a Buy, Before Earnings?---
Bulls Say, Bears Say
Bulls Say
Drug Development And TrialsXmAb942 is considered de-risked in IBD due to supporting data from similar drugs, and positive news from its trials could significantly boost shares.
Partnerships And CollaborationsThe company's antibody platform has led to several partnerships and 3 approved drugs, showcasing its effectiveness and credibility.
ValuationThe current valuation is seen as an attractive entry point due to multiple expected catalysts and partnered programs offering additional upside.
Bears Say
Clinical TrialsXencor's antibody candidates may fail in the clinic.
Drug SafetyXmAb808 shows dose-limiting tox at highest dose — not major concern
Partnership RisksThe company's partnerships may falter.
---
Ownership Overview
1.29% Insiders
34.43% Mutual Funds
0.20% Other Institutional Investors
37.11% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XNCR FAQ
What was Xencor Inc.’s price range in the past 12 months?
Xencor Inc. lowest stock price was $15.31 and its highest was $27.24 in the past 12 months.
What is Xencor Inc.’s market cap?
Xencor Inc.’s market cap is $1.11B.
When is Xencor Inc.’s upcoming earnings report date?
Xencor Inc.’s upcoming earnings report date is Mar 03, 2025 which is in 9 days.
How were Xencor Inc.’s earnings last quarter?
Xencor Inc. released its earnings results on Nov 07, 2024. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.981 by $0.271.
Is Xencor Inc. overvalued?
According to Wall Street analysts Xencor Inc.’s price is currently Undervalued.
Does Xencor Inc. pay dividends?
Xencor Inc. does not currently pay dividends.
What is Xencor Inc.’s EPS estimate?
Xencor Inc.’s EPS estimate is -0.78.
How many shares outstanding does Xencor Inc. have?
Xencor Inc. has 69,982,030 shares outstanding.
What happened to Xencor Inc.’s price movement after its last earnings report?
Xencor Inc. reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.981. Following the earnings report the stock price went up 2.205%.
Which hedge fund is a major shareholder of Xencor Inc.?
Currently, no hedge funds are holding shares in XNCR
---
Xencor Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.75 (113.74% Upside)
$33.75 (113.74% Upside)
Blogger Sentiment
Bullish
XNCR Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.80%
12-Months-Change
Fundamentals
Return on Equity
-28.47%
Trailing 12-Months
Asset Growth
26.36%
Trailing 12-Months
Company Description
Xencor Inc.
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
---
XNCR Stock 12 Month Forecast
Average Price Target
$33.75
▲(113.74% Upside)
Technical Analysis
Best Analysts Covering XNCR
1 Year
1 Year Success Rate
9/12 ratings generated profit
1 Year Average Return
+8.97%
reiterated a sell rating 4 months ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +8.97% per trade.
---